These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1310 related items for PubMed ID: 32681922

  • 1. Fecal Microbiota Transplantation Reduces Symptoms in Some Patients With Irritable Bowel Syndrome With Predominant Abdominal Bloating: Short- and Long-term Results From a Placebo-Controlled Randomized Trial.
    Holvoet T, Joossens M, Vázquez-Castellanos JF, Christiaens E, Heyerick L, Boelens J, Verhasselt B, van Vlierberghe H, De Vos M, Raes J, De Looze D.
    Gastroenterology; 2021 Jan; 160(1):145-157.e8. PubMed ID: 32681922
    [Abstract] [Full Text] [Related]

  • 2. Faecal microbiota transplantation for diarrhoea-predominant irritable bowel syndrome: a double-blind, randomised, placebo-controlled trial.
    Aroniadis OC, Brandt LJ, Oneto C, Feuerstadt P, Sherman A, Wolkoff AW, Kassam Z, Sadovsky RG, Elliott RJ, Budree S, Kim M, Keller MJ.
    Lancet Gastroenterol Hepatol; 2019 Sep; 4(9):675-685. PubMed ID: 31326345
    [Abstract] [Full Text] [Related]

  • 3. Randomised clinical trial: faecal microbiota transplantation versus autologous placebo administered via colonoscopy in irritable bowel syndrome.
    Lahtinen P, Jalanka J, Hartikainen A, Mattila E, Hillilä M, Punkkinen J, Koskenpato J, Anttila VJ, Tillonen J, Satokari R, Arkkila P.
    Aliment Pharmacol Ther; 2020 Jun; 51(12):1321-1331. PubMed ID: 32343000
    [Abstract] [Full Text] [Related]

  • 4. The effect of faecal microbiota transplantation on abdominal pain, stool frequency, and stool form in patients with moderate-to-severe irritable bowel syndrome: results from a randomised, double-blind, placebo-controlled study.
    Madsen AMA, Halkjær SI, Christensen AH, Günther S, Browne PD, Kallemose T, Hansen LH, Petersen AM.
    Scand J Gastroenterol; 2021 Jul; 56(7):761-769. PubMed ID: 34000958
    [Abstract] [Full Text] [Related]

  • 5. Faecal microbiota transplantation versus placebo for moderate-to-severe irritable bowel syndrome: a double-blind, randomised, placebo-controlled, parallel-group, single-centre trial.
    Johnsen PH, Hilpüsch F, Cavanagh JP, Leikanger IS, Kolstad C, Valle PC, Goll R.
    Lancet Gastroenterol Hepatol; 2018 Jan; 3(1):17-24. PubMed ID: 29100842
    [Abstract] [Full Text] [Related]

  • 6. Rifaximin Treatment for Individual and Multiple Symptoms of Irritable Bowel Syndrome With Diarrhea: An Analysis Using New End Points.
    Lacy BE, Chang L, Rao SSC, Heimanson Z, Sayuk GS.
    Clin Ther; 2023 Mar; 45(3):198-209. PubMed ID: 36922331
    [Abstract] [Full Text] [Related]

  • 7. Efficacy of faecal microbiota transplantation for patients with irritable bowel syndrome in a randomised, double-blind, placebo-controlled study.
    El-Salhy M, Hatlebakk JG, Gilja OH, Bråthen Kristoffersen A, Hausken T.
    Gut; 2020 May; 69(5):859-867. PubMed ID: 31852769
    [Abstract] [Full Text] [Related]

  • 8. The effect of fecal microbiota transplantation on IBS related quality of life and fatigue in moderate to severe non-constipated irritable bowel: Secondary endpoints of a double blind, randomized, placebo-controlled trial.
    Johnsen PH, Hilpüsch F, Valle PC, Goll R.
    EBioMedicine; 2020 Jan; 51():102562. PubMed ID: 31877418
    [Abstract] [Full Text] [Related]

  • 9. An Open-Labeled Study on Fecal Microbiota Transfer in Irritable Bowel Syndrome Patients Reveals Improvement in Abdominal Pain Associated with the Relative Abundance of Akkermansia Muciniphila.
    Cruz-Aguliar RM, Wantia N, Clavel T, Vehreschild MJGT, Buch T, Bajbouj M, Haller D, Busch D, Schmid RM, Stein-Thoeringer CK.
    Digestion; 2019 Jan; 100(2):127-138. PubMed ID: 30423561
    [Abstract] [Full Text] [Related]

  • 10. Faecal microbiota transplantation alters gut microbiota in patients with irritable bowel syndrome: results from a randomised, double-blind placebo-controlled study.
    Halkjær SI, Christensen AH, Lo BZS, Browne PD, Günther S, Hansen LH, Petersen AM.
    Gut; 2018 Dec; 67(12):2107-2115. PubMed ID: 29980607
    [Abstract] [Full Text] [Related]

  • 11. Bifidobacterium-Rich Fecal Donor May Be a Positive Predictor for Successful Fecal Microbiota Transplantation in Patients with Irritable Bowel Syndrome.
    Mizuno S, Masaoka T, Naganuma M, Kishimoto T, Kitazawa M, Kurokawa S, Nakashima M, Takeshita K, Suda W, Mimura M, Hattori M, Kanai T.
    Digestion; 2017 Dec; 96(1):29-38. PubMed ID: 28628918
    [Abstract] [Full Text] [Related]

  • 12. Fecal microbiota transplantation in patients with irritable bowel syndrome: an overview of current studies.
    Körner E, Lorentz A.
    J Appl Microbiol; 2023 Mar 01; 134(3):. PubMed ID: 36882216
    [Abstract] [Full Text] [Related]

  • 13. The kinetics of gut microbial community composition in patients with irritable bowel syndrome following fecal microbiota transplantation.
    Mazzawi T, Lied GA, Sangnes DA, El-Salhy M, Hov JR, Gilja OH, Hatlebakk JG, Hausken T.
    PLoS One; 2018 Mar 01; 13(11):e0194904. PubMed ID: 30427836
    [Abstract] [Full Text] [Related]

  • 14. Engraftment of strictly anaerobic oxygen-sensitive bacteria in irritable bowel syndrome patients following fecal microbiota transplantation does not improve symptoms.
    Browne PD, Cold F, Petersen AM, Halkjær SI, Christensen AH, Günther S, Hestbjerg Hansen L.
    Gut Microbes; 2021 Mar 01; 13(1):1-16. PubMed ID: 34074214
    [Abstract] [Full Text] [Related]

  • 15. Clinical response to fecal microbiota transplantation in patients with diarrhea-predominant irritable bowel syndrome is associated with normalization of fecal microbiota composition and short-chain fatty acid levels.
    Mazzawi T, Hausken T, Hov JR, Valeur J, Sangnes DA, El-Salhy M, Gilja OH, Hatlebakk JG, Lied GA.
    Scand J Gastroenterol; 2019 Jun 01; 54(6):690-699. PubMed ID: 31190584
    [Abstract] [Full Text] [Related]

  • 16. Fecal microbiota transplant delivered via invasive routes in irritable bowel syndrome: A systematic review and meta-analysis of randomized controlled trials.
    Mohan BP, Loganathan P, Khan SR, Garg G, Muthusamy A, Ponnada S, Pasam RT, Chandan S, Tuteja A.
    Indian J Gastroenterol; 2023 Jun 01; 42(3):315-323. PubMed ID: 37247177
    [Abstract] [Full Text] [Related]

  • 17. Efficacy and mode of action of mesalazine in the treatment of diarrhoea-predominant irritable bowel syndrome (IBS-D): study protocol for a randomised controlled trial.
    Leighton MP, Lam C, Mehta S, Spiller RC.
    Trials; 2013 Jan 09; 14():10. PubMed ID: 23302220
    [Abstract] [Full Text] [Related]

  • 18. Current status of fecal microbiota transplantation for irritable bowel syndrome.
    El-Salhy M, Hausken T, Hatlebakk JG.
    Neurogastroenterol Motil; 2021 Nov 09; 33(11):e14157. PubMed ID: 34236740
    [Abstract] [Full Text] [Related]

  • 19. Saccharomyces cerevisiae CNCM I-3856 in irritable bowel syndrome: An individual subject meta-analysis.
    Cayzeele-Decherf A, Pélerin F, Leuillet S, Douillard B, Housez B, Cazaubiel M, Jacobson GK, Jüsten P, Desreumaux P.
    World J Gastroenterol; 2017 Jan 14; 23(2):336-344. PubMed ID: 28127207
    [Abstract] [Full Text] [Related]

  • 20. Efficacy of the Combination of Pinaverium Bromide 100 mg Plus Simethicone 300 mg in Abdominal Pain and Bloating in Irritable Bowel Syndrome: A Randomized, Placebo-controlled Trial.
    Schmulson MJ, Chiu-Ugalde J, Sáez-Ríos A, López-Colombo A, Mateos-Pérez GJ, Remes-Troche JM, Sobrino-Cossio S, Soto-Pérez JC, Tamayo de la Cuesta JL, Teramoto-Matsubara OT, López-Alvarenga JC.
    J Clin Gastroenterol; 2020 Apr 14; 54(4):e30-e39. PubMed ID: 31385885
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 66.